News

Net Loss of Piramal Pharma reported to Rs 69.39 crore in the quarter ended June 2026 as against net loss of Rs 81.70 crore during the previous quarter ended June 2025. Sales rose 17.39% to Rs 2269.92 crore in the quarter ended June 2026 as against Rs 1933.71 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2269.921933.71 17 OPM %8.605.52 - PBDT216.0997.52 122 PBT-7.46-99.76 93 NP-69.39-81.70 15 Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 29 July 2026.

Piramal Pharma announced that USFDA has issued an Establishment Inspection Report (EIR) for the company`s manufacturing facility located at Sellersville (USA) and the inspection has now been successfully closed by USFDA.

Piramal Pharma announced that the Annual General Meeting(AGM) of the company will be held on 30 July 2026.

Piramal Pharma has allotted 21 lakh equity shares under ESOP on 05 June 2026. Consequently, the paid up equity share capital has increased to Rs. 1,331,34,81,300 (consisting of 133,13,48,130 equity shares of face value of Rs. 10/- each).